Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.
One year after its separation from Western Digital, SanDisk's shares have skyrocketed nearly 1,500%, fueled by an AI-driven memory boom. A major Wall Street upgrade now sees a path to $1,000 as supply constraints and soaring demand create a 'super-profitability' cycle.
Despite a recent earnings miss, Charles Schwab's stock has significantly outpaced the market over the past year. Wall Street maintains a cautiously optimistic stance, with upgraded ratings and bullish price targets pointing to further potential gains.
Prominent crypto analyst Tom Lee faces a wave of skepticism after his aggressive price predictions for Ethereum and Bitcoin fail to materialize amid a market downturn, sparking debate over the role of high-profile forecasts in volatile markets.
Despite a modest price target reduction, Morgan Stanley reaffirms its Overweight rating on Wingstop, citing the chicken wing chain's robust unit expansion and system-wide sales momentum as key drivers for its 2026 outlook.
Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.
JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Oppenheimer and Wells Fargo have raised price targets for Monolithic Power Systems (MPWR), highlighting robust demand from the automotive and artificial intelligence sectors as key growth drivers ahead of the company's quarterly results.
Barclays raises its price target on NorthWestern Energy Group (NWE) to $62, citing solid quarterly performance and strategic moves, including a pending merger with Black Hills Corporation, as the regulated utility reaffirms its long-term growth outlook.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.
Satellite communications provider Viasat (VSAT) saw its shares hit a new 52-week peak of $46.49, capping a remarkable 12-month rally. The surge follows a significant price target upgrade from Morgan Stanley and the successful launch of a key global network for government clients.
Takeda Pharmaceutical's (TSE:4502) recent share price rally has ignited a debate among investors. With the stock closing at ¥5,242, analysts are divided on its true worth, presenting a complex picture of fair value signals and future growth prospects.
Bank of America raises its price target on Chevron (CVX) to $188, maintaining a Buy rating, as geopolitical tensions and a planned ramp-up of Venezuelan crude exports bolster the energy giant's near-term outlook.
Citigroup reaffirms its bullish stance on AppLovin (APP), highlighting the rapid adoption of its Axon platform by e-commerce clients and improved customer quality as key growth drivers, with a price target of $820.
Oracle shares face continued pressure over debt and AI infrastructure costs, but Guggenheim's bullish $400 price target suggests potential for a multi-year rebound if execution risks are managed.
